Search

Displaying results 2911 - 2920 of 10000 in total
  1. Drug

    Ciclesonide

    go.drugbank.com/drugs/DB01410
    ApprovedInvestigational

    Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

  2. Drug

    Phenprocoumon

    go.drugbank.com/drugs/DB00946
    ApprovedInvestigationalWithdrawn

    Coumarin derivative that acts as a long-acting oral anticoagulant.

  3. Drug

    Celiprolol

    go.drugbank.com/drugs/DB04846
    ApprovedInvestigationalWithdrawn

    Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome. … In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome.

    Synonyms: RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea
  4. Drug

    Atacicept

    go.drugbank.com/drugs/DB06399
    ApprovedInvestigational

    [L63797,L63928] The approval is conditional on a proven reduction of proteinuria in the Origin 3 trial, which is evaluating whether the atacicept slows long-term kidney function decline. … [L63797] Reducing BAFF- and APRIL-mediated signaling lowers production of galactose-deficient IgA1, an aberrant antibody whose deposition in the kidney drives IgA nephropathy.

    Synonyms: TACI-IG
  5. Drug

    Inactivated SARS-Cov-2 Vaccine

    go.drugbank.com/drugs/DB15862
    Investigational

    This strain was isolated from a patient in Wuhan, cultivated in a Vero cell line, and then subsequently inactivated using B-propiolactone. … [A220158] Currently, the vaccine is being tested in Phase 3 clinical trial in Abu Dhabi (ChiCTR2000034780).[A219758]

  6. Drug

    Cabazitaxel

    go.drugbank.com/drugs/DB06772
    ApprovedInvestigational

    [A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376] … [A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010.

  7. Drug

    Cabotegravir

    go.drugbank.com/drugs/DB11751
    ApprovedInvestigational

    [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in

  8. Drug

    Afamitresgene autoleucel

    go.drugbank.com/drugs/DB18592
    ApprovedInvestigational

    [L51114] MAGE-A4 is an intracellular cancer-testis antigen that is overexpressed by cancer cells in synovial sarcoma. … [L51114] On August 2, 2024, the FDA granted the accelerated approval of afamitresgene autoleucel, making it the first FDA-approved TCR gene therapy and the first gene therapy for the treatment of synovial

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE
  9. Drug

    Bromfenac

    go.drugbank.com/drugs/DB00963
    ApprovedWithdrawn

    Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation.

  10. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    On August 8, 2001 the U.S. … It has also been withdrawn from the Canadian market.[A669,L43942]